US2020289515A1PendingUtilityA1
Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
Est. expiryJul 16, 2028(~2 yrs left)· nominal 20-yr term from priority
A61K 33/244A61K 33/243A61K 33/242A61K 33/241A61K 31/519A61P 35/02A61P 17/00A61K 31/704A61P 1/00A61P 43/00A61K 39/39558A61P 15/00A61K 31/52A61P 29/00A61K 31/00A61K 31/337A61K 31/675A61K 45/06A61K 39/3955A61P 35/00A61P 11/00A61P 37/00A61K 33/24
77
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
Claims
exact text as granted — not AI-modified1 .- 26 . (canceled)
27 . A method for treating a solid tumor in a subject comprising administering to the subject a compound having the structure:
wherein the solid tumor is selected from colon cancer, breast cancer, and non-small cell lung cancer.
28 . The method of claim 27 , wherein the solid tumor is breast cancer and following administration of the compound, the subject achieves a partial response or a complete response.
29 . A method for treating colon cancer in a subject comprising administering to the subject a compound having the structure:
30 . The method of claim 29 , further comprising administering to the subject an additional anti-cancer agent.
31 . The method of claim 30 , wherein the additional anti-cancer agent is docetaxel.
32 . The method of claim 29 , wherein following administration of the compound, the subject achieves a partial response or a complete response.Join the waitlist — get patent alerts
Track US2020289515A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.